Archive for the 'New Research' Category

Deep Vein Thrombosis & Pulmonary Embolism in Pregnancy: Controversies continue

Nice to see the people at the NEJM continue to provide us with clinically relevant topics across all specialities: none more so than the complication of DVT in pregnant women.The review article (link here) highlights management and thromboprophylaxis in the NEJM. What is more interesting to my eyes is the actual planned investigation of suspected PE in patients who do not have a clinically proven DVT.

An interesting viewpoint for our British Readers can be found at the BTS guidelines in the management of pulmonary embolism here. Note how the issue of imaging in pregnancy is not exactly clear cut!

Nevertheless despite the use of a Well’s score, and ultrasound dopplers of the lower limbs, the jury is still out on the imaging modality of choice for pregnant women with suspected pulmonary embolism (i.e. CT Pulmonary Angiography (CTPA) , Limited CTPA, Limited Nuclear Medicine Scanning, MRI). The risks from nuclear medicine imaging seem likely to be higher than CT given the added problems of a reduced sensitivity and specificity, whereas the use of MRI is limited in the UK by the relative paucity of units offering this as a service/ lack of scanning facilities in some smaller hospitals.

Even though a lead apron will protect the foetus there are still concerns from CT about maternal breast tissue in this situation.

In the absence of hard and fast rules, this is an area of medicine that continues to challenge clinicans on a dya to day basis.

Almetuzamab: Promise in Multiple Sclerosis; UK Research

Published this week in the New England Journal of Medicine, promising trial data for the new monoclonal antibody Almetuzamab.The conclusions of the study were as follows:

In patients with early, relapsing–remitting multiple sclerosis, alemtuzumab was more effective than interferon beta-1a but was associated with autoimmunity, most seriously manifesting as immune thrombocytopenic purpura. The study was not powered to identify uncommon adverse events.”

NEJM abstract link here

There has been extensive media coverage of the drug on UK media sources including coverage of patients who have received the drug. Cambridge researchers showed a reduction in relapse rate and disability in 334 patients suffering from multiple sclerosis for less than 3 years.